We are live on ! Find out more
ECM

EagleClaw Capital Management Portfolio holdings

AUM $714M
1-Year Est. Return 24.24%
This Fund
S&P 500
This Quarter Est. Return
+3.65%
1 Year Est. Return
+24.24%
3 Year Est. Return
+96.54%
5 Year Est. Return
+138.84%
10 Year Est. Return
+573.51%
AUM
$230M
AUM Growth
+$10.7M
Cap. Flow
+$4.47M
Cap. Flow %
1.95%
Top 10 Hldgs %
35.18%
Holding
126
New
6
Increased
45
Reduced
39
Closed
4

Top Buys

Rank Stock Value
1
TPL icon
Texas Pacific Land
TPL
+$1.26M
2
BKNG icon
Booking.com
BKNG
+$858K
3
INGR icon
Ingredion
INGR
+$757K
4
NVDA icon
NVIDIA
NVDA
+$719K
5
WRK
WestRock Company
WRK
+$469K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$444K
2
NKE icon
Nike
NKE
+$365K
3
KO icon
Coca-Cola
KO
+$316K
4
COP icon
ConocoPhillips
COP
+$246K
5
LTHM
Livent Corporation
LTHM
+$237K

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 15.91%
2 Financials 15.71%
3 Industrials 14.92%
4 Technology 13.69%
5 Healthcare 12.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CVX icon
26
Chevron
CVX
$392B
$2.48M 1.08%
19,966
+210
+1% +$25.4K
HON icon
27
Honeywell
HON
$77B
$2.39M 1.04%
14,556
+239
+2% +$38K
MRK icon
28
Merck
MRK
$322B
$2.38M 1.03%
29,632
TMO icon
29
Thermo Fisher Scientific
TMO
$213B
$2.33M 1.01%
7,950
-200
-2% -$55.1K
FDX icon
30
FedEx
FDX
$72.7B
$2.33M 1.01%
14,185
GILD icon
31
Gilead Sciences
GILD
$162B
$2.22M 0.97%
32,802
+6,225
+23% +$410K
CL icon
32
Colgate-Palmolive
CL
$73.1B
$2.13M 0.93%
29,702
FMC icon
33
FMC
FMC
$1.34B
$2.1M 0.92%
25,395
NVO
34
Novo Nordisk
NVO
$208B
$2.07M 0.9%
81,148
+150
+0.2% +$3.71K
IBM icon
35
IBM
IBM
$211B
$2.07M 0.9%
15,627
+3,368
+27% +$442K
NVS icon
36
Novartis
NVS
$297B
$1.98M 0.86%
21,715
-2,519
-10% -$213K
QCOM icon
37
Qualcomm
QCOM
$155B
$1.93M 0.84%
25,315
+776
+3% +$56.8K
JNJ icon
38
Johnson & Johnson
JNJ
$618B
$1.92M 0.83%
13,749
-525
-4% -$72.7K
WM icon
39
Waste Management
WM
$90.6B
$1.9M 0.83%
16,476
-300
-2% -$32.6K
CERN
40
DELISTED
Cerner Corp
CERN
$1.83M 0.8%
24,975
+400
+2% +$27K
NVDA icon
41
NVIDIA
NVDA
$4.86T
$1.81M 0.79%
440,720
+173,600
+65% +$719K
HOLX
42
DELISTED
Hologic
HOLX
$1.77M 0.77%
36,900
PANW icon
43
Palo Alto Networks
PANW
$270B
$1.72M 0.75%
50,910
+3,210
+7% +$120K
CI icon
44
Cigna
CI
$73.7B
$1.69M 0.73%
10,686
+1,944
+22% +$305K
WMB icon
45
Williams Companies
WMB
$87.5B
$1.69M 0.73%
60,387
-425
-0.7% -$11.8K
CVS icon
46
CVS Health
CVS
$133B
$1.69M 0.73%
31,122
-3,316
-10% -$179K
CAT icon
47
Caterpillar
CAT
$375B
$1.69M 0.73%
12,385
-1,000
-7% -$132K
LMT icon
48
Lockheed Martin
LMT
$134B
$1.66M 0.72%
4,561
MKC icon
49
McCormick & Company Non-Voting
MKC
$13.7B
$1.63M 0.71%
21,052
+100
+0.5% +$7.71K
GOOGL icon
50
Alphabet (Google) Class A
GOOGL
$4.36T
$1.62M 0.71%
30,120
-2,120
-7% -$123K

Similar funds

EagleClaw Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, EagleClaw Capital Management held 126 positions worth $230M, up 4.9% from $219M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

EagleClaw Capital Management's Q2 2019 filing shows 6 new, 45 increased, 39 reduced and 4 closed positions. Its largest new stake was Walt Disney: 1,861 shares worth $261K. The largest sale was Celgene Corp, an estimated $444K.

By sector, the portfolio is most concentrated in Consumer Discretionary at 16% of assets, up from 16% a quarter earlier, followed by Financials and Industrials.

  • EagleClaw Capital Management's largest Q2 2019 buy was Walt Disney: 1,861 shares worth $261K.
  • EagleClaw Capital Management added most to Texas Pacific Land in Q2 2019, an estimated $1.26M increase.
  • EagleClaw Capital Management's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $444K.
  • EagleClaw Capital Management fully exited ConocoPhillips in Q2 2019, selling an estimated $246K.
  • EagleClaw Capital Management's ten largest holdings make up 35% of its $230M portfolio in Q2 2019.
  • EagleClaw Capital Management opened 6 new positions and closed 4 in Q2 2019.
  • EagleClaw Capital Management's portfolio value rose 4.9% quarter-over-quarter to $230M.

Based on EagleClaw Capital Management's 13F filing for Q2 2019, filed 18 Jul 2019.